April 4, 2025

Company Name: HEALIOS K.K.
Representative: Hardy TS Kagimoto, Chairman & CEO
(TSE Growth Code: 4593)

Notice of Upcoming R&D Briefing on ARDS

HEALIOS K.K. ("Healios") is pleased to announce that it will host an R&D briefing on Acute Respiratory Distress Syndrome (ARDS) for both domestic and international investors, as well as members of the media. The event will provide an overview of Healios' latest initiatives and progress in ARDS-related research and development. In addition, we will present the upcoming "REVIVE-ARDS" Phase 3 clinical trial, primarily planned for the United States. These insights will be shared through talks by U.S.-based key opinion leaders (KOL), former ARDS patients, and members of our research and development team.

Date & Time:
Wednesday, April 9, 2025 | 4:00 PM – 6:00 PM (JST)

Format: Online, *Simultaneous interpretation will be provided.*
If you would like to attend, please register using the link below.
https://us06web.zoom.us/webinar/register/WN_kkYT5A9GSByF6je0UB2Q_g
After registration, a viewing URL will be sent to your registered email address via Zoom. On the day of the event, please join using the provided URL. Please kindly note that the session will be available for viewing only, and questions will be limited to institutional investors media representatives.

Event Program :

16:00 ～	Introduction to Healios' ARDS Program	Healios CEO Hardy TS Kagimoto
16:05 ～ KOL Presentation	ARDS, the current standard of care, and the unmet medical need.	Lorraine B. Ware, MD. Vanderbilt University.
16:20 ～ KOL Presentation	The promise of cell therapy in ARDS.	Michael A. Matthay, MD. University of California San Francisco.
16:35～	Q&A	-
16:45～ Business Overview	The science and data in support of invimestrocel in ARDS.	Sarah Busch, PhD. Chief Scientific Officer, Healios N.A.
17:00 ～ Business Overview	REVIVE-ARDS, a global Phase 3 study to confirm the efficacy of invimestrocel in pneumonia-induced ARDS.	Eric Jenkins, MD. Medical Consultant, Healios N.A.
17:15 ～ Patient Experience Talk	An ARDS patient experience and the need for a new therapy.	Eileen Rubin. President & CEO, ARDS Foundation.
17:30 ～ Patient Experience Talk	A soldier's experience and the need for new therapies to serve the United States military.	DJ Skelton. Advisor, Healios K.K.
17:45 ～	Q&A	-
17:55	Closing Remarks	Healios CFO Richard Kincaid

Contact:
IR & PR Division
HEALIOS K.K.
E-mail: ir@healios.jp